Jun 25th 2010 - Edison Investment Research today published a report on Bionomics entitled "BCN210 Study Plans". In summary, the report says:
Bionomics is selecting doses for two planned Phase Ib studies of its anxiety compound BNC210, which are due to begin enrolment shortly and are expected to report results in Q1 next year. The studies will be conducted in healthy volunteers, but will provide some efficacy data through use of an induced-anxiety model and measurement of cortisol. Meanwhile, Phase II studies of the VDA BNC105 in renal carcinoma and mesothelioma are both recruiting well and should provide some interim data in late 2010 and early 2011 respectively. These data are likely to be important in Bionomics' efforts to establish a corporate partnership.
Edison is Europe's leading independent investment research company. It has won industry recognition, with awards in both the UK and internationally. The team of 60 includes over 35 analysts supported by a department of supervisory analysts, editors and assistants.
...read more